The company retains a close association with the Sanger Institute and its founders and is based at the Wellcome Genome Campus, Cambridge UK.

In June, 2018, Microbiotica announced a collaboration with the Roche unit Genentech, potentially worth more than $500 million, to discover, develop and commercialize biomarkers, targets and medicines for inflammatory bowel disease.